Annovis Bio Files 8-K on Operations
Ticker: ANVS · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-condition, operations
TL;DR
Annovis Bio filed an 8-K on Aug 12, 2025, reporting financial condition and operations.
AI Summary
Annovis Bio, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, but does not disclose specific financial figures or operational updates within the provided text.
Why It Matters
This 8-K filing indicates Annovis Bio is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting operational and financial information, with no immediate negative or positive news indicated in the provided text.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 101 Lindenwood Drive, Suite 225 (address) — Principal Executive Offices
- Malvern, PA (location) — City, State of Principal Executive Offices
- QR Pharma, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing by Annovis Bio, Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Annovis Bio, Inc., and it includes Financial Statements and Exhibits.
On what date was this 8-K report filed or effective?
The report was filed as of August 12, 2025, and the date of the earliest event reported is also August 12, 2025.
What is the principal executive office address for Annovis Bio, Inc.?
The principal executive office address is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What was Annovis Bio, Inc.'s former company name?
Annovis Bio, Inc.'s former company name was QR Pharma, Inc.
What is the SIC code for Annovis Bio, Inc.?
The Standard Industrial Classification (SIC) code for Annovis Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2025-08-12 16:16:48
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2523281d1_8k.htm (8-K) — 25KB
- tm2523281d1_ex99-1.htm (EX-99.1) — 58KB
- 0001104659-25-076851.txt ( ) — 252KB
- anvs-20250812.xsd (EX-101.SCH) — 3KB
- anvs-20250812_lab.xml (EX-101.LAB) — 33KB
- anvs-20250812_pre.xml (EX-101.PRE) — 22KB
- tm2523281d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated August 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: August 12, 2025 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer